Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXYS Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Lel H who wrote (228)	1/12/1999 12:38:00 PM
From: bob zagorin	Respond to of 455

exactly. Axys Pharm Stk Dwn 17%; Profit-Taking Likely, Analyst Says Dow Jones Newswires NEW YORK -- Shares of Axys Pharmaceutical Inc. (AXPH) dipped 15 percent Tuesday, apparently the victim of some profit-taking after gains following the company's announcement Jan. 7 it will provide Rhone-Poulenc S.A.'s (RP) Rhone-Poulenc Rorer unit with a compound screening library. "The most likely explanation is that there's a bit of profit-taking going on," said David Stone, an analyst at SG Cowen & Co. Stone also said with small-cap companies like Axys, it only takes a handful of investors to take their chips off the table and thus move the stock. The analyst added he's heard of no news from the company Monday. Axys could not be immediately reached for comment. Axys will provide Rhone-Poulenc with structurally diverse compounds and enabling technologies for re-creating the library. Rhone-Poulenc, Paris, develops, makes and sells drugs, herbicides and insecticides. Axys Pharmaceuticals researches and develops synthetic small molecule drugs. Axys shares recently traded at 6 7/8, down 1 3/16, or 14.7% on a volume of 158,600 shares. Average daily volume is 147,521. It traded at a 52-week low of 3 3/8 on Sept. 2, 1998. The shares gained 3/16 on Monday, after adding 1/16 on Friday and 1 1/16 on Thursday, Jan. 7.